Skip to main content
Premium Trial:

Request an Annual Quote

Tufts' Clinical and Translational Science Institute Lands $24M from NIH

NEW YORK (GenomeWeb News) – Tufts University Medical Center has received $24 million from the National Institutes of Health to fund its Clinical and Translational Science Institute (CTSI), which hosts core facilities for nucleic acid analysis, a biorepository, training and consultation programs, and other services, Tufts said on Wednesday.

Tufts said its CTSI collaborates with 39 partners, which includes 12 schools and research centers at the university, 10 affiliated hospitals, and five industry partners, among others.

Richard Karas, the chief scientific officer at Tufts Medical Center, said the CTSI, which first received funding in 2008, provides support for clinical trials, lab research, study design, funding for pilot studies, and career development programs.

The CTSI's core center, the Clinical and Translational Research Center, provides a range of services, including specimen processing, storage, and shipping, nucleic acid analysis, immunoassays, and access to bench and freezer space. The CTSI's specimen processing services include DNA and RNA isolation, and its nucleic acid analysis offerings include DNA and RNA analysis, real-time PCR assays, whole genome amplification, and library preparation for next-generation sequencing.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more